ScholarIQanswers from OpenAlex
Alexion Pharmaceuticals
FunderResearch funding and supported work
Alexion Pharmaceuticals is a funder indexed in ScholarIQ from OpenAlex.
What is known about Alexion Pharmaceuticals?
ScholarIQrecord summary
American company
How many works does Alexion Pharmaceuticals have?
ScholarIQindexed works
Alexion Pharmaceuticals has 4,545 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Alexion Pharmaceuticals?
ScholarIQopenalex
The OpenAlex for Alexion Pharmaceuticals is on the source record.
What is the ROR of Alexion Pharmaceuticals?
ScholarIQror
The ROR for Alexion Pharmaceuticals is on the source record.
What are the most-cited papers on Alexion Pharmaceuticals?
ScholarIQmost cited works
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
Brad H. Rovin, Sharon G. Adler, Jonathan Barratt, Frank Bridoux, Kelly A. Burdge, Tak Mao Chan, H. Terence Cook, Fernando C. Fervenza, Keisha L. Gibson, Richard J. Glassock, David Jayne, Vivekanand Jha, Adrian Liew, Zhi-Hong Liu, Juan M. Mejía‐Vilet, Carla Nester, Jai Radhakrishnan, Elizabeth M. Rave, Heather N. Reich, Pierre Ronco, Jan‐Stephan Sanders, Sanjeev Sethi, Yusuke Suzuki, Sydney Tang, Vladimı́r Tesař, Marina Vivarelli, Jack F.M. Wetzels, Lyubov Lytvyn, Jonathan C. Craig, David J. Tunnicliffe, Martin Howell, Marcello Tonelli, Michael Cheung, Amy Earley, Jürgen Floege
<i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes
Nicolas Marcoux, Scott Gettinger, Grainne M. O’Kane, Kathryn C. Arbour, Joel W. Neal, Hatim Husain, Tracey L. Evans, Julie R. Brahmer, Alona Muzikansky, Philip Bonomi, Salvatore Del Prete, Anna Wurtz, Anna F. Farago, Dora Dias‐Santagata, Mari Mino–Kenudson, Karen L. Reckamp, Helena A. Yu, Heather A. Wakelee, Frances A. Shepherd, Zofia Piotrowska, Lecia V. Sequist
KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary
Vicente E. Torres, Curie Ahn, Thijs R.M. Barten, Godela Brosnahan, Melissa A. Cadnapaphornchai, Arlene B. Chapman, Émilie Cornec-Le Gall, Joost P.H. Drenth, Ron T. Gansevoort, Peter C. Harris, Tess Harris, Shigeo Horie, Max C. Liebau, Michele Liew, Andrew Mallett, Changlin Mei, Djalila Mekahli, Dwight Odland, Albert Ong, Luiz F. Onuchic, York Pei, Ronald D. Perrone, Gopala K. Rangan, Brian Rayner, Roser Torrá, Ethan M. Balk, Craig E. Gordon, Amy Earley, Reem A. Mustafa, Olivier Devuyst
Complement dysregulation in glomerulonephritis
Kati Kaartinen, Adrian Safa, Soumya Kotha, Giorgio Ratti, Seppo Meri
Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA–Associated Vasculitis
Jürgen Floege, David Jayne, Jan‐Stephan Sanders, Vladimı́r Tesař, Ethan M. Balk, Craig E. Gordon, Gaelen P. Adam, Marcello Tonelli, Michael Cheung, Amy Earley, Brad H. Rovin